Sinco Pharmaceuticals cancels HK$170 million 18-month convertibles

Chicago, March 13 – Sinco Pharmaceuticals Holdings Ltd. announced it has terminated its placing of new shares and convertibles bonds initially announced on Jan. 29, 2019, according to a company news release.

The company entered into a termination agreement on March 13 with its placement agent, South China Securities Ltd.

Sinco Pharmaceuticals will explore alternative financing activities to refinance its existing debt, settling a proposed acquisition and for general working capital.

Sinco Pharmaceuticals is a Chengdu, China-based investment holding company that provides marketing and promotion for imported pharmaceutical products in China.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.